Society of Hematologic Oncology

New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.

Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.